Please try another search
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.
Name | Age | Since | Title |
---|---|---|---|
Paul John Rennie | 64 | 2014 | Founder, MD & Executive Chairman |
Helen Fisher | - | 2021 | Independent Non-Executive Director |
Donna L. Skerrett | 66 | 2020 | Chief Medical Officer and Executive Director |
Amos Meltzer | 57 | 2020 | Independent & Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review